Please assess the completion status of the following clinical trial:

Trial Title: Treatment Method Research of Invasive Pulmonary Fungal Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. More than 18 years old ，male or female~2. Expected the time of staying in ICU longer than 72 hours and the duration of mechanical ventilation for more than 48 hours~3. Pulmonary infection according to, axillary temperature≥ 37℃, using broad-spectrum antibiotics more than 72 hours, no better or worse~4. Candida score greater than or equal to 3~5. Child-bearing women, urine pregnancy test must be negative when screening and agreed to adopt safe and effective contraceptive measures in the process~6. Male subjects must be guaranteed to use dual physical methods of contraception contraceptive and sperm donation, from starting to after 30days ending treatment~7. Subjects ( or their legal representatives） have signed the informed consent~Exclusion Criteria:~1. Diagnosed with invasive fungal infection by any of the following means at the time of admission 1）Proved deep fungal infection by histopathology 2）Peripheral blood culture fungi positive at least 1 time 3）Specimens from sterile sites of culture positive ( cerebrospinal fluid, pleural effusion and ascites）~2. Renal insufficiency, creatinine clearance \< 30ml/min~3. Active liver disease or suspected drug induced liver injury~4. Pregnant and lactating women~5. With imidazole or pyrrolic drug allergy or intolerance or have contraindications.~6. Not fit into the group by comprehensive judgment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- empirical therapy (Type: None): immediate initiation of antifungal therapy; Itraconazole :1-14day,iv；(400mg/day bid 1-2day, 200mg/day q.d 3-14day) 15-28day,p.o(400mg/day bid)
- preemptive therapy (Type: None): Dynamic monitoring of fungal infection, initiation antifungal therapy when clinical diagnosis ( microbial + experiment +, G/GM, CT typical change ) approveled in two weeks Itraconazole :1-14day,iv；(400mg/day bid 1-2day, 200mg/day q.d 3-14day) 15-28day,p.o(400mg/day bid) If within two weeks without obtaining positive results, researchers determine whether initiation of antifungal therapy。

Based on this trial design, predict the completion outcome and termination type (if applicable).